Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04933552 (ClinicalTrials.gov)	December 15, 2021	18/6/2021	Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent	Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent (Siponimod): An OTIS Observational Pregnancy Surveillance Study	Multiple Sclerosis	Other: Siponimod	Novartis Pharmaceuticals	NULL	Recruiting	N/A	N/A	Female	867		United States
2	NCT04895202 (ClinicalTrials.gov)	November 19, 2021	17/5/2021	Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study	Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study	Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity	Other: Siponimod	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	60		Switzerland